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TB-Free World. You can make history. End TB”
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journal home page: www.elsevier .com/ locat e/ i j idWorld TB Day, March 24th commemorates the day in March
1882 when Professor Robert Koch made the groundbreaking
announcement in Berlin of his discovery of Mycobacterium
tuberculosis as the cause of Tuberculosis (TB) (Koch, 1882). At
the time of his announcement, there was a deadly TB epidemic,
rampaging throughout Europe and the Americas, causing the death
of one out of every seven people. Since Koch’s announcement,
Mycobacterium tuberculosis has deﬁed worldwide efforts by public
health systems, researchers, governments and the World Health
Organization (WHO) to eradicate it. The data presented in the WHO
Global TB Report 2017 (World Health Organization, 2017a) makes
very gruesome reading. In 2016 there were an estimated 10.4
million people who developed TB disease worldwide, of which 90%
were adults, 35% female and 10% were HIV-co-infected people. An
estimated 40% of active TB cases go undiagnosed each year. One
hundred and thirty-six years since Koch’s announcement, TB
remains a major global public health issue and TB has surpassed
HIV/AIDS and malaria as the world’s top cause of death from an
infectious disease! On World TB Day, March 24th, 2018, we need to
reﬂect on the current status quo of the continuing devastating
global TB epidemic.
For a disease which has had effective treatment available for the
past 50 years, TB exerts a huge and unacceptable global impact on
morbidity and mortality rates. In 2016, TB caused the unnecessary
deaths of an estimated 1.7 million people of which 0.4 million were
among people living with HIV (World Health Organization, 2017a).
Thirty high TB burden countries accounted for 87% of the 10.4
million incident TB cases globally. Five countries, India, Indonesia,
China, the Philippines and Pakistan accounted for 56% of the 10.4
million cases. Of these, China, India and Indonesia accounted for
45% of total global cases in 2016 and Nigeria and South Africa each
accounted for 4% (Koch, 1882). Drug-resistant TB (DR-TB) has been
reported from every corner of the globe and has become an
ominous threat to global health security. In 2016, there were
600,000 new cases with resistance to rifampicin (RR-TB), of which
490,000 had multidrug-resistant TB (MDR-TB) deﬁned as resis-
tance to rifampicin and isoniazid. Worryingly, three high TB
endemic countries with strong and growing economies, India,
China and the Russian Federation, had almost half (47%) of the
490,000 MDR-TB cases. Extensively drug resistant TB (XDR-TB,
deﬁned as MDR-TB plus resistance to any ﬂuoroquinolone and at
least one of three injectable second-line drugs, amikacin,https://doi.org/10.1016/j.ijid.2018.03.002
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(World Health Organization, 2017a). A total of 8,014 cases of XDR-
TB were reported by 72 countries, with 75% of cases from the WHO
European and South-East Asia regions, with the largest numbers of
XDR-TB being reported from India, China, Belarus, South Africa and
Ukraine.
In May 2014, the 67th World Health Assembly endorsed the
WHO End TB Strategy, which set bold targets and envisions a TB-
free world. This strategy was adopted by United Nations (UN)
member states, and governments called for the rather ambitious
2030 targets for ending the TB epidemic, with a 90% reduction in TB
deaths compared with levels in 2015 (World Health Organization,
2014). Accordingly patient-centred care and prevention, and
supportive systems targets, were placed alongside research and
innovation. This recognized that apart from political commitment
and strengthening of national TB programs, achieving substantial
reductions in TB mortality and incidence will require development
and evaluation of new diagnostics, treatment regimens and
vaccines, and at the same time ensuring rollout with universal
access to, and the optimal use of existing tools. High TB burden
countries such as Brazil, India, China, South Africa and Russia have
thriving technological and pharmaceutical industries and in-
creased investments are required by the public and private sectors
into local pharma focused on development of new TB tools.
In light of the current slow progress in global TB control efforts,
achieving the ambitious WHO End TB (World Health Organization,
2014) targets appears to be almost impossible. It has been long
recognized that the global TB epidemic will only be brought under
control if the underlying socio-economic determinants are
addressed seriously by all governments (Grange and Zumla,
1999; Grange et al., 2009). TB is a disease of poverty thriving
within communities that are disadvantaged socio-economically,
are marginalized and have poor access to good quality health and
social services (Grange et al., 2009; Raviglione et al., 2012). The risk
of TB is further increased by other factors such as malnutrition,
poor housing and sanitation, tobacco smoking, alcohol use and
diabetes, and poor access to care (Ortblad et al., 2015). TB patients
have to bear loss of income, and costs associated with illness and
lack of social protection, resulting in a vicious cycle of poverty and
disease (Grange and Zumla, 1999). Between 2000 to 2015, 33
million people have died of TB and TB has cost the global economy
an estimated 617 billion dollars (Global TB Caucus, 2018).ious Diseases. This is an open access article under the CC BY-NC-ND license (http://
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Conference (Petersen et al., 2017; World Health Organization,
2017b) held in Moscow on ‘Ending TB in the Sustainable Develop-
ment Era’ the declaration and commitments made by Ministers of
Health and delegates representing 114 countries (World Health
Organization, 2017b)were focused on four main issues:
 First, to strengthen health systems so that appropriate health
coverage is universal thus providing improved access to TB
treatment and prevention care.
 Second, to ensure that there is enough ﬁnancing for this and the
resources are sustainable in the long term through increased
national and international investment for healthcare implemen-
tation and research.
 Third, to increase investment in research into new tools to
diagnose, treat and prevent TB.
 Fourth to create a multi-sectoral framework to provide account-
ability through tracking, auditing and constantly reviewing
progress being made. A major paradigm shift in the political and
funder attention for achieving global TB control will be required
to attain these deliverables.
The Ministerial Declaration arising from the Moscow confer-
ence (World Health Organization, 2017b) will be taken forward
further at the United Nations General Assembly (UNGA) high-
level meeting on TB in September 2018. This will be ‘a historic and
unprecedented’ meeting since it is the ﬁrst ever UN meeting
focused only on TB. There are high expectations much optimism
that at this UNGA (UN General Assembly, 2018), all governments
will show true commitment and bold leadership by contributing
substantially to mobilizing and sustaining the much-needed
resources for ending the global TB pandemic and achieving the
WHO End-TB targets. High TB endemic countries with healthier
economies, such as India, Russia, Indonesia, Brazil, China, and
South Africa are expected to demonstrate the long-awaited
leadership and contribute substantially to mobilizing resources
for TB using innovative approaches to ﬁnancing with a more
diverse funding base. This will generate goodwill and encourage
all high TB endemic countries to follow suit and commit the
resources required to achieve the WHO EndTB strategy goals. The
laudable commitment by all high TB endemic countries to the
Moscow Declaration and the increased participation of their
parliamentarians in the Global TB Caucus (TB, 2018a) should be
followed up with stepping-up investments in their own national
health programs. This will need to be twinned with a biosocial
approach (Ortblad et al., 2015) to controlling TB involving social,
economic, and poverty alleviation actions, with multi-sectoral
coordination with other governmental sectors and involvement of
civil society. The roles of regional public health and disease
control institutions in all continents to support operationalization
of these global TB ambitions and goals will become increasingly
important. For example, the recently established Africa Center for
Disease Control (CDC) (CDC, 2018) and its regional centers,
working alongside other regionally relevant African programs
such as the WHO Supranational Reference Laboratory Network
(WHO, 2018) and The European and Developing Countries Clinical
Trials Partnership (EDCTP) regional Networks of Excellence
(EDCTP, 2018) could generate and enhance a tailored and
coordinated approach to TB surveillance, research and control
activities (Zumla et al., 2015). These in turn will support
individual countries to address both national and region-speciﬁc
challenges while building much needed local capacity and
expertise (Zumla et al., 2015).
World TB Day March 24th 2018 provides an opportunity for the
international community to reﬂect seriously about why, after over
25 years since TB was declared a global emergency by the WHO, TBPlease cite this article in press as: S. Tiberi, et al., Taking forward the Stop T
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ijid.2018.03.002is today the most common single infectious disease cause of death
globally? This year the Stop TB Partnership and the World Health
Organization, for the ﬁrst time, are leading together a joint theme
for the 2018 World TB Day campaign: “Wanted: Leaders for a TB-
free world. You can make history. End TB” (TB, 2018c; TB, 2018b).
This theme is well thought out and very appropriate for visionary
leaders to emerge from all continents whose efforts and
commitment can eventually bring an end to millions of unneces-
sary deaths due to the persistent global TB pandemic. The
impending UNGA high level meeting provides a unique opportu-
nity for governments of all high TB endemic countries to take up
the longstanding complex challenges of controlling the global TB
pandemic and prove themselves to be ‘Leaders for a TB-free
world’, make history and End TB!.
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